Last reviewed · How we verify
NCT03714399: VARIANCE
Muscle Recovery Following Aortic Surgery Induced ICUAW.
trial in Aortic Diseases in 31 participants. Completed in 26 September 2022.
22 June 2022
Quick facts
| Lead sponsor | Barts & The London NHS Trust |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 31 |
| Start date | 19 February 2019 |
| Primary completion | 22 June 2022 |
| Estimated completion | 26 September 2022 |
| Sites | 1 location across United Kingdom |
Conditions studied
- Aortic Diseases — all drugs for Aortic Diseases →
- Intensive Care Unit Syndrome — all drugs for Intensive Care Unit Syndrome →
- Intensive Care Neuropathy — all drugs for Intensive Care Neuropathy →
- Intensive Care (ICU) Myopathy — all drugs for Intensive Care (ICU) Myopathy →
Sponsor
Barts & The London NHS Trust — full company profile →
Who can join
18 and older, any sex, with Aortic Diseases or Intensive Care Unit Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To identify determinants of 'good and bad recovery' from ICUAW and build knowledge around the timing of these processes. Also, the investigators want to discover the effects of ICUAW on physical function and HRQoL following aortic surgery.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Mitochondrial Dysfunction Contributes to Sustained Muscle Loss After Cardiac Surgery: A Prospective Observational Study.
Thomas AN, Kalakoutas A, Yates M, Yap J, et al · · 2025 · cited 1× · PMID 40842041 · DOI 10.1002/jcsm.70051
Verify or expand the search:
- PubMed search for NCT03714399
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Aortic Diseases
Currently open trials in the same condition.
- NCT07117825 — Aortic Dissection fAlse enlarGement radIomics predictiOn · active not recruiting
- NCT06199401 — Safety and Efficacy of XJ-Procedure in Patients With Acute Type A Aortic Dissection Surgery · NA · recruiting
- NCT07034430 — Aortic Dilatation Under 5 cm: Genetic Risk Mapping · active not recruiting
- NCT05972018 — Liposomal Bupivacaine/Bupivacaine in Rectus Sheath Blocks Versus Ropivacaine in Rectus Sheath Blocks And Catheters · Phase 4 · recruiting
- NCT06358248 — Standardized Physician-modified Fenestrated Endograft Registry · recruiting
Other Barts & The London NHS Trust trials
Trials by the same sponsor.
- NCT05753085 — Multimodality Optical and Ultrasound Intravascular Imaging for Stent Optimization and Atheroma Assessment · NA · withdrawn
- NCT07047235 — Substrate Remodelling and Targeted Ablation in AF · NA · recruiting
- NCT06871215 — Inflammation and Infective Endocarditis · withdrawn
- NCT07076524 — MuScle WastIng and DysphaGia iN CriticAlly IlL Patients (SIGNAL) · recruiting
- NCT06596486 — A Comparison of CoolStick With Ethyl Chloride for the Assessment of Light Touch · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03714399 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Barts & The London NHS Trust
- Last refreshed: 4 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03714399.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing